Cancers, Vol. 13, Pages 626: Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer

xloma.fota13 shared this article with you from Inoreader Cancers, Vol. 13, Pages 626: Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer Via Cancers Cancers, Vol. 13, Pages 626: Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer Cancers doi: 10.3390/cancers13040626 Authors: Ami Patel Puja Iyer Shinya Matsuzaki Koji Matsuo Anil K. Sood Nicole D. Fleming Epithelial ovarian cancer remains a leading cause of death amongst all gynecologic cancers despite advances in surgical and medical therapy. Historically, patients with ovarian cancer underwent primary tumor reductive surgery followed by postoperative chemotherapy; however, neoadjuvant chemotherapy followed by interval tumor reductive surgery has gradually become an alternative approach for patients with advanced-stage ovarian cancer for whom primary tumor reductive surgery is not feasible. Decision-making about the use of these approaches has not been uniform. Hence, it is essential to identify patients who can benefit most from neoadjuvant chemotherapy followed by interval tumor reductive surgery. Several prospective and retrospective studies have proposed potential models to guide upfront decision-making for patients with advanced ovarian cancer. In this review, we summarize important decision-making models that can improve patient selection for personalized treatment. Models based on clinical factors (clinical parameters, radiology studies and laparoscopy scoring) and molecular markers (circulating and tumor-based) are useful, but laparoscopic staging is among the most informative diagnostic methods for upfront decision-making in patients medically fit for surgery. Further research is needed to explore more reliable models to determine personalized treatment for advanced epithelial ovarian cancer. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.